Drug Profile
Interferon alpha-2b biobetter - HanAll Biopharma
Alternative Names: Hanferon; HL031 (oral interferon alpha-2b) - HanAll Biopharma; HL143 (subcutaneous interferon alpha-2b) - HanAll Biopharma; Modified interferon-alpha - HanAll Biopharma; Resis-IFN-alpha-2bLatest Information Update: 11 Sep 2017
Price :
$50
*
At a glance
- Originator Nautilus Biotech
- Developer HanAll Biopharma; Nautilus Biotech
- Class Antivirals; Biobetters; Interferons
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cancer; Hepatitis C; Liver cancer
Most Recent Events
- 11 Sep 2017 Discontinued - Phase-II for Hepatitis C in USA (SC)
- 11 Sep 2017 Discontinued - Phase-II for liver cancer (Prevention of relapse) in USA (SC)
- 10 Aug 2015 Phase-II development of SC interferon alpha-2b is ongoing in USA